Publikationen in Zusammenarbeit mit Forschern von Hospital Ramón y Cajal (40)

2024

  1. Author Correction: Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer (Nature Medicine, (2023), 29, 7, (1738-1749), 10.1038/s41591-023-02407-3)

    Nature Medicine

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2023

  1. Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer

    Nature Medicine, Vol. 29, Núm. 7, pp. 1738-1749

  2. Percutaneous diagnosis of an atypical presentation of pulmonary aspergillosis mimicking lung cancer in a renal transplant patient

    Transplant Infectious Disease, Vol. 25, Núm. 3

  3. Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer

    Revista Espanola de Patologia, Vol. 56, Núm. 1, pp. 58-68

  4. Three synchronous Lung Cancers in the Same Lung Segment: Triple Trouble?

    Archivos de Bronconeumologia, Vol. 59, Núm. 7, pp. 458-460

  5. Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils

    Archivos de Bronconeumologia, Vol. 59, Núm. 8, pp. 502-509

2022

  1. Acute Dyspnea and Hemoptysis in an 84-Year-Old Man With Multiple Comorbidities

    Chest, Vol. 161, Núm. 2, pp. e97-e101

  2. Cytological and molecular characterization of secretory breast carcinoma

    Diagnostic Cytopathology, Vol. 50, Núm. 7, pp. E174-E180

  3. Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: Diagnostic challenges of a novel fusion

    Human Pathology Reports, Vol. 28

  4. Progression to lung fibrosis in severe COVID-19 patients: A morphological and transcriptomic study in postmortem samples

    Frontiers in Medicine, Vol. 9

  5. Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab

    Current Problems in Cancer: Case Reports, Vol. 5

2021

  1. ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors

    Current Problems in Cancer: Case Reports, Vol. 4

  2. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design

    Future Oncology, Vol. 17, Núm. 12, pp. 1459-1472

  3. Percutaneous Biopsy of a Paraaortic Mediastinal Mass Using a Contralateral Parasternal Approach: A New Alternative Safe Access

    Archivos de Bronconeumologia

  4. Pulmonary vascular proliferation in patients with severe COVID-19: An autopsy study

    Thorax, Vol. 76, Núm. 10, pp. 1044-1046

  5. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1474-1480

  6. Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 5, pp. 437-444

2020

  1. COVID-19: Thoracic Diagnostic Interventional Procedures in Troubled Times

    Archivos de Bronconeumologia, Vol. 56, Núm. 10, pp. 674-676

  2. Challenges in Management of Patients With Lung Cancer in Times of COVID-19: An Imaging Perspective

    Clinical Lung Cancer